Antibe Therapeutics Inc.
1063 King St. West
Suite 210
Hamilton
Ontario
L8S 4S3
Canada
Tel: 905-515-6132
Fax: 905-528-9862
Website: http://www.antibe-therapeutics.com/
200 articles about Antibe Therapeutics Inc.
-
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
8/24/2020
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020
-
Antibe Therapeutics Announces Results of Annual and Special Meeting
8/20/2020
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu); The re-appointment of Ernst & Young LLP, Chartered Ac
-
Antibe Therapeutics Engages Stern IR for Investor Relations Services
8/6/2020
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. “We are excited to have engaged Stern IR as our new investor relations firm to support us in enhancing our visibility within the US clinical and financial communities,” said
-
Antibe Therapeutics Provides Corporate Update - Aug 04, 2020
8/4/2020
As we transition into a Phase III company, we want to take the opportunity to highlight recent progress and to outline our strategy as we pursue monetization of our promising drug candidates and hydrogen sulfide platform.
-
Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results
7/24/2020
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020
-
Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
6/2/2020
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session for analysts.
-
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
6/1/2020
Antibe Therapeutics Inc. is pleased to announce that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study.
-
BioSpace Movers & Shakers, May 8
5/8/2020
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Antibe Therapeutics Announces the Hiring of Chief Medical Officer
5/6/2020
Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering
-
Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study
5/4/2020
Antibe Therapeutics Inc. provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.
-
Clinical Catch-Up: February 24-28
3/2/2020
The month of February ended with a flurry of clinical trial announcements. Here’s a look. -
Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346
2/28/2020
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, ATB-346.
-
Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results
2/25/2020
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019.
-
Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug
2/24/2020
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide‐Releasing Anti- Inflammatory Drug (ATB‐352): A Role for Endogenous Cannabinoids”.
-
Antibe Therapeutics Recognized as a TSX Venture 50 Company for Second Consecutive Year
2/21/2020
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50™ company for the second consecutive year, in recognition of its performance on the TSX Venture Exchange.
-
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering
1/13/2020
The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for our overall drug platform.
-
Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results
11/28/2019
Antibe Therapeutics Inc., a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.
-
Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results
8/27/2019
The Company’s unaudited fiscal Q1 2020 condensed interim consolidated financial statements and MD&A are available on SEDAR.
-
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346
8/27/2019
Antibe Therapeutics Inc. provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.
-
Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results
7/17/2019
Antibe Therapeutics Inc. filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019.